**SUPPLEMENTAL DATA**

**Table e-1 Summary of literature**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Reference** | **No. Of Patients** | **Favorable treatment responsea** | **Relapse** | **Adverse effects and mortality** | **Follow-up (months)** |
| Sodhi, 2008 (15) | 4 | 4/4 (100%) | 0/4 (0%) | None | N/Ab |
| Panselinas, 2009 (16) | 6 | 5/6 (83%) | 6/6 (100%) | N/A | 5 - 25 |
| Moravan, 2009 (17) | 7 | 7/7 (100%) | 2/7 (29%)c | 1/7 (14%), no mortality | 24-39 |
| Santos, 2010 (11) | 4 | 2/4 (50%) | 0/4 (0%) | None | N/A |
| Hostettler, 2012 (10) | 6 | 5/6 (83%) | 0/6 (0%) | 0/6 (0%), no mortality | 13-59 |
| Russell, 2013 (18) | 8 | 5/8 (63%) | N/A | N/A | N/A |
| Riancho-Zarrabeitia, 2014 (12) | 5 | 2/5 (40%) | 3/5 (60%) | 2/5 (40%), no mortality | 2-24 |
| Aubart, 2016 (13) | 18 | 16/18 (89%) | 9/18 (50%) | 8/18 (44%), no mortality | 6-93 |
| Gelfand, 2017 (14) | 66 | 51/66 (77%) | 9/16 (56%)c | 8/66 (12%), no mortality | N/Ad |

Only case series describing 4 or more patients were included in the table. N/A is not available.

a Defined as improvement or clinical remission.

b No time of follow-up was mentioned. 13-16 infusions were administered and clinical change was monitored.

c When infliximab was discontinued.

d IFX exposure with a median of 1,5 years with an interquartile range of 0.8-2.6.